Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 9Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Colorectal Neoplasms 5Lymphoma 4Liver Neoplasms 4Lung Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma 2Locally Advanced Rectal Cancer 2Hematologic Diseases 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor, Adult 1

Interventions

Cisplatin 38Fluorouracil 37Radiotherapy 33Oxaliplatin 23Paclitaxel 20Irinotecan 18Leucovorin 17Docetaxel 17Capecitabine 10Neoadjuvant Therapy 9Surgical Procedures, Operative 8Cetuximab 8Chemotherapy, Adjuvant 7Radiation 6Carboplatin 6Immunohistochemistry 5Erlotinib Hydrochloride 5Biopsy 5Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Folfox protocol 4Epirubicin 4Drug Therapy 4pembrolizumab 3Trastuzumab 3Microarray Analysis 3Gefitinib 3Fluorodeoxyglucose F18 3Endoscopy, Digestive System 3ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma Of Esophagus × spartalizumab × Clear all
NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Novartis

Phase 2 Completed
76 enrolled 14 charts
GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡